onc Videos

Videos

Eric Lander, MD, Vanderbilt University Medical Center

Videos

Tumor Mutational Signatures Among Patients With Early-Onset Versus Average-Onset Colorectal Cancer

08/21/2023

At the 2023 World Congress on Gastrointestinal Cancers, Eric Lander, MD, presents genomic clustering data suggesting that early-onset colorectal cancer may be caused by unique mutagenic processes compared to average-onset colorectal cancer.

At the 2023 World Congress on...

08/21/2023

Oncology

Antonella Cammarota, MD, Humanitas University

Videos

Impact of Prior Chemotherapy Administration on Intratumor Heterogeneity of CLDN18.2-Positive Gastroesophageal Cancers

08/21/2023

Antonella Cammarota , MD;

At the 2023 World Congress on Gastrointestinal Cancers, Antonella Cammarota, MD, presented results from a study relating prior chemotherapy administration with heterogeneity of CLDN18.2 among patients with resectable gastroesophageal cancers.

At the 2023 World Congress on...

08/21/2023

Oncology

Videos

FDA Approval of GPRC5D-Targeting Bispecific Antibody Talquetamab for Patients With R/R MM

08/21/2023

Ajai Chari , MD;

Ajai Chari, MD, discusses the significance of the accelerated approval of talquetamab for the treatment of patients with R/R multiple myeloma, as well as offers advice for practicing oncologists regarding using this therapy.

Ajai Chari, MD, discusses the...

08/21/2023

Oncology

Bruno Sangro, MD, PhD, Clínica Universidad de Navarra

Videos

Long-Term OS Benefit of STRIDE Regimen Among Patients With Unresectable Hepatocellular Carcinoma

08/21/2023

Bruno Sangro , MD, PhD;

At the 2023 World Congress on Gastrointestinal Cancers, Bruno Sangro, MD, PhD, discusses 4-year overall survival results from the phase 3 HIMALYA study.

At the 2023 World Congress on...

08/21/2023

Oncology

Videos

New Developments in Risk Stratification and Management of High-Risk and Low-Risk MDS

08/19/2023

Amer Zeidan , MBBS;

At the 2023 Great Debates & Updates in Hematologic Malignancies Meeting, Amer Zeidan, MBBS, speaks on recent developments in risk stratification and treatment management among patients with high-risk and low-risk myelodysplastic syndromes.

At the 2023 Great Debates &...

08/19/2023

Oncology

Videos

Diagnosing and Treating Patients With Indolent and Advanced Systemic Mastocytosis

08/19/2023

Daniel DeAngelo , MD, PhD;

At the 2023 Great Debates & Updates in Hematologic Malignancies meeting, Daniel DeAngelo, MD, PhD, shares insights into recent treatment developments and diagnostic criteria for patients with indolent and systemic mastocytosis.

At the 2023 Great Debates &...

08/19/2023

Oncology

Videos

Analyzing the Role of BTK Inhibitors and Combination Therapies in the Frontline Treatment of Patients With CLL

08/18/2023

John N. Allan , MD;

At the 2023 Great Debates & Updates in Hematologic Malignancies Meeting, John Allan, MD, analyzes the role of BTK inhibitors and combination therapies in the frontline treatment of patients with chronic lymphocytic leukemia.

At the 2023 Great Debates &...

08/18/2023

Oncology

Videos

Choosing Treatment Options and Managing Toxicities for Patients With R/R Follicular Lymphoma

08/18/2023

Carla Casulo , MD;

At the 2023 Great Debates & Updates in Hematologic Malignancies meeting, Carla Casulo, MD, summarizes the available treatment options for relapsed/refractory follicular lymphoma and options for managing various treatment-related toxicities.

At the 2023 Great Debates &...

08/18/2023

Oncology

Videos

Individualized Treatment Approaches for Patients With Hodgkin Lymphoma

08/18/2023

Elizabeth A. Brem , MD;

At the 2023 Great Debates & Updates in Hematologic Malignancies Meeting, Elizabeth Brem, MD, provides insights into treatment approaches used for cases of patients with Hodgkin lymphoma.

At the 2023 Great Debates &...

08/18/2023

Oncology

Videos

Predicting Outcomes for Patients With Mantle Cell Lymphoma Using Integrative Prognostic Machine Learning Models

08/18/2023

Holly Hill , PhD;

Holly Hill, PhD, shares findings from a study on the value and clinical utility of integrative prognostic machine learning models as a tool for determining accurate predictions of outcomes among patients with MCL.

Holly Hill, PhD, shares findings...

08/18/2023

Oncology

Recent News

News

FDA Grants Approval to Revumenib for Patients With R/R Acute Leukemia With KMT2A Translocation

11/17/2024

On November 15, 2024, the FDA approved menin inhibitor revumenib for adult and pediatric patients 1 year and older with relapsed/refractory acute leukemia with KMT2A translocation.

On November 15, 2024, the FDA...

11/17/2024

Oncology

News

Intraoperative Radiation Therapy May Improve Survival For Certain Patients With Recurrent Cervical or Endometrial Cancer

11/14/2024

Allison Casey ;

According to a retrospective study, there was an appreciable survival gain for well-selected patients with recurrent or persistent endometrial or cervical cancer who receive intraoperative radiation therapy.

According to a retrospective...

11/14/2024

Oncology

News

Amrubicin Plus Irinotecan Demonstrates Promising Efficacy, Safety for Chemotherapy-Naïve Patients With Extensive-Disease Small Cell Lung Cancer

11/14/2024

Stephanie Holland ;

According to results from the phase 2 LC 08-01 trial, amrubicin plus irinotecan demonstrated promising efficacy and safety among chemotherapy-naïve patients with extensive-disease small cell lung cancer.

According to results from the...

11/14/2024

Oncology

News

Addition of Bempegaldesleukin to Nivolumab Does Not Benefit Cisplatin-Ineligible Patients With First-Line Advanced Urothelial Carcinoma

11/13/2024

Stephanie Holland ;

Results from the phase 2 PIVOT-10 trial demonstrated that the addition of bempegaldesleukin to first-line nivolumab did not improve outcomes for cisplatin-ineligible patients with locally advanced or metastatic urothelial carcinoma.

Results from the phase 2...

11/13/2024

Oncology

News

Mirdametinib for Adult and Pediatric Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas

11/12/2024

Allison Casey ;

According to a phase 2b trial, mirdametinib demonstrated significant confirmed objective response rates with deep and durable reductions of volume of target plexiform neurofibromas and clinically meaningful improvements to health-related...

According to a phase 2b trial,...

11/12/2024

Oncology

News

Epirubicin Plus Cyclophosphamide and Docetaxel Reduces Long-Term Risk of Recurrence for Patients With TOP2A Normal Early Breast Cancer

11/12/2024

Stephanie Holland ;

According to final results from the DBCG 07-READ trial, the addition of epirubicin to cyclophosphamide and docetaxel reduced long-term risk of breast cancer recurrence among patients with TOP2A normal early breast cancer.

According to final results from...

11/12/2024

Oncology

News

Pembrolizumab Plus Chemotherapy For Patients With High-Risk Endometrial Cancer

11/11/2024

Allison Casey ;

According to results from a phase 3 trial, pembrolizumab plus chemotherapy did not improve DFS among patients with high-risk endometrial cancer. However, there may be a benefit among patients with mismatch report-deficient disease.

According to results from a...

11/11/2024

Oncology

FDA Approval

FDA Grants Approval to Obecabtagene Autoleucel for R/R B-Cell Precursor Acute Lymphoblastic Leukemia

11/08/2024

On November 8, 2024, the FDA approved CD19-directed genetically modified autologous T cell immunotherapy obecabtagene autoleucel for the treatment of patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia.

On November 8, 2024, the FDA...

11/08/2024

Oncology

News

Naporafenib in Combination With Rineterkib or Tremetinib for KRAS- or BRAF-Mutant Non-Small Cell Lung Cancer

11/07/2024

Allison Casey ;

While naporafenib plus rineterkib and naporafenib plus trametinib both had acceptable safety profiles, antitumor activity was limited among patients with KRAS-/BRAF-mutant non-small cell lung cancer.

While naporafenib plus...

11/07/2024

Oncology

News

Addition of Concurrent Thoracic Radiotherapy to First-Line TKI Therapy Improves Survival for Patients With EGFR-Mutated Non-Small Cell Lung Cancer

11/06/2024

Stephanie Holland ;

According to results from a phase 3 trial, the addition of concurrent thoracic radiotherapy to first-line icotinib improved survival among patients with EGFR-mutated oligo-organ metastatic non-small cell lung cancer.

According to results from a...

11/06/2024

Oncology